Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 18, 2025

SU-DHL-4

RRID:CVCL_0539
Type: Cell Line

Proper Citation

(RRID:CVCL_0539)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0539

Proper Citation: (RRID:CVCL_0539)

Sex: Male

Defining Citation: PMID:83902, PMID:177185, PMID:214220, PMID:371794, PMID:2875799, PMID:2985879, PMID:3159941, PMID:3874327, PMID:3881165, PMID:8547074, PMID:8957066, PMID:9738977, PMID:9787181, PMID:10739008, PMID:11226526, PMID:12169673, PMID:17363600, PMID:18357372, PMID:19278952, PMID:20054396, PMID:20628145, PMID:20889926, PMID:22460905, PMID:23292937, PMID:25355872, PMID:25485619, PMID:25877200, PMID:25894527, PMID:26589293, PMID:26727417, PMID:27397505, PMID:28196595, PMID:28356514, PMID:29416618, PMID:29666304, PMID:30165192, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:31978347, PMID:35839778

Comments: Omics: Virome analysis using RNAseq., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Cell surface proteome., Omics: Array-based CGH., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: SU-DHL-4

Synonyms: SUDHL4, Sudhl4, SUDHL-4, Sudhl-4, SuDHL 4, SUD-4, SUD4, SU4, Stanford University-Diffuse Histiocytic Lymphoma-4, DHL-4, DHL4

Cross References: BTO:BTO_0006462, CLO:CLO_0037061, EFO:EFO_0006492, MCCL:MCC:0000440, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2957, BioGRID_ORCS_Cell_line:742, BioSample:SAMN03473232, BioSample:SAMN10988472, cancercelllines:CVCL_0539, CCRID:3101HUMSCSP5048, Cell_Model_Passport:SIDM00405, ChEMBL-Cells:CHEMBL3308053, ChEMBL-Targets:CHEMBL613711, CLS:305106, Cosmic:850203, Cosmic:932763, Cosmic:999780, Cosmic:1067443, Cosmic:1079254, Cosmic:1517656, Cosmic:1541909, Cosmic:1636687, Cosmic:1714160, Cosmic:1945192, Cosmic:2276338, Cosmic:2361375, Cosmic:2437313, Cosmic-CLP:1331035, DepMap:ACH-000365, DSMZ:ACC-495, DSMZCellDive:ACC-495, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS265MKB, ENCODE:ENCBS980NLV, GDSC:1331035, GEO:GSM274842, GEO:GSM380145, GEO:GSM499735, GEO:GSM552463, GEO:GSM562826, GEO:GSM887653, GEO:GSM888745, GEO:GSM1035322, GEO:GSM1374906, GEO:GSM1670485, IARC_TP53:25031, IARC_TP53:28236, ICLC:HTL10002, LiGeA:CCLE_386, LINCS_LDP:LCL-1136, Lonza:270, PharmacoDB:SUDHL4_1502_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_0539, PubChem_Cell_line:CVCL_0539, Ubigene:YC-C082, Wikidata:Q54970717

ID: CVCL_0539

Record Creation Time: 20250131T202727+0000

Record Last Update: 20250131T204704+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-4.

Warning: Discontinued: ICLC; HTL10002
Omics: Virome analysis using RNAseq., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Cell surface proteome., Omics: Array-based CGH., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Layden HM, et al. (2024) Mutant FOXO1 controls an oncogenic network via enhancer accessibility. Cell genomics, 4(4), 100537.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Li J, et al. (2024) Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nature communications, 15(1), 2879.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Rane G, et al. (2024) ZBTB48 is a priming factor regulating B-cell-specific CIITA expression. The EMBO journal, 43(24), 6236.

Martins F, et al. (2024) A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation. Cancer research, 84(6), 808.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular cancer therapeutics, 23(5), 683.

Ding Y, et al. (2024) A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma. Scientific reports, 14(1), 21184.

Li Y, et al. (2024) USP19 exerts a tumor-promoting role in diffuse large B cell lymphoma through stabilizing PARK7. The FEBS journal, 291(21), 4757.

Yang X, et al. (2023) Potential role of the P2X7 receptor in the proliferation of human diffused large B-cell lymphoma. Purinergic signalling.

Delage L, et al. (2023) BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. Blood, 141(10), 1209.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Li J, et al. (2023) Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas. bioRxiv : the preprint server for biology.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Suh JL, et al. (2022) Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell chemical biology, 29(4), 555.

Lu H, et al. (2022) Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-?B axis. Cell host & microbe, 30(8), 1139.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 185(9), 1521.

Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. Science advances, 8(39), eabq0117.